Cash, cash equivalents, restricted cash and short-term investments totaled $84.5 million as of March 31, 2025, before accounting for the proceeds pending the close of the PRV sale. As of December 31, 2024, cash, cash equivalents, restricted cash and short-term investments totaled $98.1 million.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABEO:
- Abeona, Lurie Children’s opens first center for ZEVASKYN gene therapy
- Abeona Therapeutics: Strong Buy Rating Backed by Financial Stability and Strategic Growth Initiatives
- Abeona Therapeutics Sells Priority Review Voucher for $155M
- Abeona Therapeutics enters agreement to sell PRV for $155M
- ABEO Earnings this Week: How Will it Perform?